Role of Chemokine Receptor CCR4 and Regulatory T Cells in Wound Healing of Diabetic Mice.


Journal

The Journal of investigative dermatology
ISSN: 1523-1747
Titre abrégé: J Invest Dermatol
Pays: United States
ID NLM: 0426720

Informations de publication

Date de publication:
05 2019
Historique:
received: 08 03 2018
revised: 14 09 2018
accepted: 02 10 2018
pubmed: 23 11 2018
medline: 8 5 2020
entrez: 23 11 2018
Statut: ppublish

Résumé

Wound healing is a well-coordinated process that involves inflammatory mediators and cellular responses; however, if any disturbances are present during this process, tissue repair is impaired. Chronic wounds are one of the serious long-term complications associated with diabetes mellitus. The chemokine receptor CCR4 and its respective ligands, CCL17 and CCL22, are involved in regulatory T cell recruitment and activation in inflamed skin; however, the role of regulatory T cells in wounds is still not clear. Our aim was to investigate the role of CCR4 and regulatory T cells in cutaneous wound healing in diabetic mice. Alloxan-induced diabetic wild- type mice (diabetic) developed wounds that were difficult to heal, differently from CCR4

Identifiants

pubmed: 30465800
pii: S0022-202X(18)32823-9
doi: 10.1016/j.jid.2018.10.039
pii:
doi:

Substances chimiques

Chemokine CCL17 0
Chemokine CCL22 0
Chemokines 0
Receptors, CCR4 0
Alloxan 6SW5YHA5NG

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1161-1170

Informations de copyright

Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Janaína F Barros (JF)

Institute of Biomedical Sciences, Pharmacology and Inflammation Program, Federal University of Rio de Janeiro, Center for Health Sciences, Rio de Janeiro, Rio de Janeiro, Brazil.

Ingrid Waclawiak (I)

Institute of Biophysics Carlos Chagas Filho, Immunobiology Program, Federal University of Rio de Janeiro, Center for Health Sciences, Rio de Janeiro, Rio de Janeiro, Brazil.

Cyntia Pecli (C)

Institute of Biomedical Sciences, Pharmacology and Inflammation Program, Federal University of Rio de Janeiro, Center for Health Sciences, Rio de Janeiro, Rio de Janeiro, Brazil.

Paula A Borges (PA)

Institute of Biomedical Sciences, Pharmacology and Inflammation Program, Federal University of Rio de Janeiro, Center for Health Sciences, Rio de Janeiro, Rio de Janeiro, Brazil.

Janaína L Georgii (JL)

Institute of Biomedical Sciences, Pharmacology and Inflammation Program, Federal University of Rio de Janeiro, Center for Health Sciences, Rio de Janeiro, Rio de Janeiro, Brazil.

Erivan S Ramos-Junior (ES)

Institute of Biophysics Carlos Chagas Filho, Immunobiology Program, Federal University of Rio de Janeiro, Center for Health Sciences, Rio de Janeiro, Rio de Janeiro, Brazil.

Claudio Canetti (C)

Institute of Biophysics Carlos Chagas Filho, Immunobiology Program, Federal University of Rio de Janeiro, Center for Health Sciences, Rio de Janeiro, Rio de Janeiro, Brazil.

Tristan Courau (T)

Sorbonne Universités, University of Pierre and Madam Curie, University of Paris, Paris, France.

David Klatzmann (D)

Sorbonne Universités, University of Pierre and Madam Curie, University of Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale les Unités Mixtes de Recherche S959, Paris, France.

Steven L Kunkel (SL)

Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA.

Carmen Penido (C)

Center for Technological Development in Health, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil; Laboratory of Applied Pharmacology, Institute of Drug Technology, Farmanguinhos, Rio de Janeiro, Rio de Janeiro, Brazil.

Fábio B Canto (FB)

Institute of Microbiology Paulo de Góes, Immunology Department, Federal University of Rio de Janeiro, Center for Health Sciences, Rio de Janeiro, Rio de Janeiro, Brazil; Department of Immunobiology, Institute of Biology, Fluminense Federal University, Niterói, Rio de Janeiro, Brazil.

Claudia F Benjamim (CF)

Institute of Biomedical Sciences, Pharmacology and Inflammation Program, Federal University of Rio de Janeiro, Center for Health Sciences, Rio de Janeiro, Rio de Janeiro, Brazil; Institute of Biophysics Carlos Chagas Filho, Immunobiology Program, Federal University of Rio de Janeiro, Center for Health Sciences, Rio de Janeiro, Rio de Janeiro, Brazil. Electronic address: cfbenjamim@biof.ufrj.br.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH